The Epidermal Growth Factor Receptor (EGFR) gene plays a crucial role in cell proliferation and growth by activation of the Ras-Raf-MAPK pathway. EGFR mutations in exon 18, 19, 20 and 21 are found with a prevalence of 10% to 30% in non-small-cell lung cancer (NSCLC) patients. The most prominent activating EGFR mutations are deletions in exon 19 and L858R in exon 21. NSCLC patients with activating EGFR mutations may benefit from TKI therapy. However, approximately 50% of the patients that acquire resistance to these TKI exhibit the T790M mutation.
The EGFR T790M RealFast™ Assay detects the most common resistance mutation in plasmaderived, cirbulating cell-free DNA (cfDNA) from NSCLC patients. This can be used for the monitoring of lung cancer patients who undergo treatment with EGFR tyrosine kinase inhibitors.
Goffin Molecular Technologies offers this test as well as other RealFast™ Assays. To see the RealFast™ Assays for cancer click here.
Copyright © 2020 Goffin Molecular Technologies